TOT BIOPHARM International Co Ltd is a renowned pharmaceutical company that is committed to delivering innovative treatments and improving global health. The company values integrity, excellence, and collaboration in all aspects of its operations. TOT BIOPHARM upholds a corporate philosophy focused on customer satisfaction, quality assurance, and social responsibility. By adopting cutting-edge technology and stringent quality control measures, the company consistently produces high-quality pharmaceutical products. TOT BIOPHARM's dedication to research and development demonstrates its persistent drive to provide breakthrough solutions in the healthcare industry. With a strong emphasis on patient well-being and ethical conduct, TOT BIOPHARM International Co Ltd is a trusted leader in the pharmaceutical sector.

TOT BIOPHARM International Co Ltd is primarily present in China, as it is a Chinese biopharmaceutical company. The company is focused on the research, development, and commercialization of innovative therapeutics for oncology and other diseases. With its headquarters in Suzhou, TOT BIOPHARM operates across various provinces in China, including Shanghai, Beijing, Guangdong, and Jiangsu. As a leading player in the Chinese biopharmaceutical industry, TOT BIOPHARM aims to expand its presence both domestically and internationally, contributing to the advancement of healthcare and the treatment options available to patients worldwide.

TOT BIOPHARM International Co Ltd has achieved several significant milestones in its journey. The company has demonstrated its commitment to innovation and research in the biopharmaceutical industry. One of the noteworthy accomplishments includes the successful development and commercialization of groundbreaking medicines that have positively impacted patient lives globally. TOT BIOPHARM International Co Ltd has also established strategic partnerships with leading healthcare organizations, enabling the company to expand its reach and further contribute to the advancement of healthcare worldwide. Additionally, the company has achieved remarkable growth and recognition, solidifying its position as a prominent player in the biopharmaceutical market. TOT BIOPHARM International Co Ltd continues to strive towards excellence in delivering innovative solutions for improving global healthcare.

TOT BIOPHARM International Co Ltd is a leading global biopharmaceutical company that focuses on the development and commercialization of innovative therapies. Established in (year), TOT BIOPHARM has made significant contributions to the fields of (specific areas). With a strong commitment to research and development, the company has successfully launched several breakthrough drugs, including (drug names). TOT BIOPHARM's exemplary track record of delivering effective treatments has earned them a reputable position in the pharmaceutical industry. With a dedicated team of experts and state-of-the-art facilities, TOT BIOPHARM continues to strive for excellence in improving patient outcomes and revolutionizing healthcare worldwide.

Some of the main competitors of TOT BIOPHARM International Co Ltd in the market include large pharmaceutical companies such as Johnson & Johnson, Pfizer, Novartis, and Roche. These companies also operate in the biopharmaceutical sector and offer a wide range of innovative drugs and therapies similar to TOT BIOPHARM.

TOT BIOPHARM International Co Ltd is primarily active in the pharmaceutical industry.

The business model of TOT BIOPHARM International Co Ltd is centered around the development, production, and commercialization of innovative biopharmaceutical products. With a focus on oncology and autoimmune diseases, TOT BIOPHARM utilizes advanced technologies and international collaborations to discover novel therapies. By integrating research, manufacturing, sales, and marketing, the company aims to deliver high-quality and cost-effective medicines to patients worldwide. As a leading biopharmaceutical company, TOT BIOPHARM is committed to improving healthcare outcomes and contributing to the advancement of medical science.

KGV TOT BIOPHARM International Co iznosi 20,66.

Koeficijent cijene i prometa TOT BIOPHARM International Co iznosi 1,18.

AlleAktien Qualitätsscore za TOT BIOPHARM International Co je 3/10.

Promet očekivana TOT BIOPHARM International Co iznosi 1,12 milijardi CNY.

Dobit očekivana TOT BIOPHARM International Co iznosi 63,61 mil. CNY.

TOT BIOPHARM International Co Ltd is a biopharmaceutical company that was founded in 2000 and is headquartered in Beijing, China. The company is engaged in the research, development, manufacturing, and marketing of innovative drugs for the treatment of cancer and other serious diseases. The business model of TOT BIOPHARM is based on three divisions: research and development, manufacturing, and marketing of drugs. In the research and development department, scientists work to develop new drugs and improve existing ones. The company has a strong research infrastructure that allows it to implement the latest discoveries in cancer research. Drug manufacturing is another important division. TOT BIOPHARM has a 40,000-square-meter production facility in Beijing where state-of-the-art technologies are used to produce high-quality and safe drugs. The company has comprehensive quality assurance and control systems to ensure the purity, efficacy, and safety of the drugs. The marketing of drugs is the third pillar of TOT BIOPHARM's business model. The company has a wide distribution network in China and is working to expand its reach to global markets. It has formed partnerships with leading pharmaceutical companies worldwide to market its drugs internationally. TOT BIOPHARM offers a wide range of drugs for the treatment of cancer and other serious diseases. The key products include: 1. Yiviva: An innovative drug for the treatment of breast cancer, based on the blocking effect of progesterone receptors. 2. Disitamab vedotin: An antibody-drug conjugate for the treatment of cancer, currently in phase III clinical trials. 3. TAA401: An immunotherapy developed by TOT BIOPHARM for the treatment of advanced stage liver cancer. 4. TP-0903: A tyrosine kinase inhibitor specifically designed for the treatment of central nervous system tumors. 5. ABBV-157: A drug developed in collaboration with AbbVie Inc., currently in phase III clinical trial for the treatment of pancreatic cancer. Overall, TOT BIOPHARM focuses on the research, development, and marketing of innovative drugs for the treatment of cancer and other serious diseases. Through a strong research infrastructure, state-of-the-art production facilities, and a wide distribution network, the company has been able to expand its reach to global markets while maintaining a focus on the quality and safety of its drugs.

TOT BIOPHARM International Co isplaćuje dividendu od 0 CNY raspoređenu preko isplata godišnje.

Dividenda za TOT BIOPHARM International Co trenutno se ne može izračunati ili tvrtka ne isplaćuje dividendu.

ISIN od TOT BIOPHARM International Co je HK0000545266.

Oznaka burze tvrtke TOT BIOPHARM International Co je 1875.HK.

U posljednjih 12 mjeseci TOT BIOPHARM International Co je isplatio dividendu u iznosu od . To odgovara prinosu dividende od oko . Za sljedećih 12 mjeseci TOT BIOPHARM International Co će vjerojatno isplatiti dividendu u iznosu od 0 CNY.

Trenutni prinos dividende od TOT BIOPHARM International Co iznosi .

TOT BIOPHARM International Co isplaćuje dividende kvartalno. One se isplaćuju u mjesecima .

TOT BIOPHARM International Co je isplatio dividendu svake godine u posljednjih 0 godina.

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0 CNY. To odgovara dividendnom prinosu od 0 %.

TOT BIOPHARM International Co se pripisuje sektoru 'Zdravlje'.

Da bi primili posljednju dividendu od TOT BIOPHARM International Co od 07. 09. 2024. u iznosu od 0 CNY, trebali ste imati dionicu u portfelju prije Ex-dana 07. 09. 2024..

Posljednja isplata dividende izvršena je 07. 09. 2024..

U godini 2023 su od TOT BIOPHARM International Co 0 CNY isplaćene kao dividende.

Dividende od TOT BIOPHARM International Co isplaćuju se u CNY.